ArticleBlood2013
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.
Article in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 213 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain
Evaluation of a Standardized Low-Dose Bolus Ketamine Pathway for Management of Pediatric Sickle Cell Patients Presenting to the Emergency Department With Pain
Who cites it
213 citing papers in PubMed, 7 syntheses or guidelines pooled it, 408 citations in OpenAlex.
- The Indian experience with hydroxyurea in sickle cell disease: A 25-year systematic review.The Indian journal of medical research · 2025Pooled it
- Silent cerebral infarcts in patients with sickle cell disease: a systematic review and meta-analysis.BMC medicine · 2020Pooled it
- Health-Related Quality of Life of Children and Adolescents with Sickle Cell Disease in the Middle East and North Africa Region: A systematic review.Sultan Qaboos University medical journal · 2020Pooled it
- Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.BMJ open · 2020Pooled it
- Safety and effectiveness of antimalarial therapy in sickle cell disease: a systematic review and network meta-analysis.BMC infectious diseases · 2018Pooled it
- Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe.Haematologica · 2017Pooled it
- Role of innate immunity-triggered pathways in the pathogenesis of Sickle Cell Disease: a meta-analysis of gene expression studies.Scientific reports · 2015Pooled it
- Trial
- Trial
- High levels of proinflammatory cytokines IL-6 and IL-8 are associated with a poor clinical outcome in sickle cell anemia.Annals of hematology · 2020Trial
- Low-impact laparoscopic cholecystectomy is associated with decreased postoperative morbidity in patients with sickle cell disease.Surgical endoscopy · 2018Trial
- Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.The New England journal of medicine · 2017Trial
- Multimodal imaging features to diagnose abdominal complications of sickle cell disease.Abdominal radiology (New York) · 2026Review
- Evaluating high-sensitivity troponin levels in people with sickle cell disease in the emergency department.British journal of haematology · 2026Article
- Sickle cell visualization in vivo in humans: microvascular occlusion formation and hemorheological indices.Blood advances · 2026Article
- Lights, camera, occlusion! watch sickle cells in real time.Blood advances · 2026Article
- Geographic and Temporal Differences in Sickle Cell Disease Hospitalizations in New York State.JAMA network open · 2026Article
- Decoupling Detection and Classification to Improve Morphological Phenotype Analysis of Sickle Red Blood Cells in Full-Scope Microscopy.bioRxiv : the preprint server for biology · 2026Article
- Beneficial effects of SGLT1/2 and SGLT2 inhibitors on vaso-occlusive events and organ damage in sickle cell disease mice.Cardiovascular research · 2026Article
- Frequency of Alloimmunization in Patients on Regular Blood Transfusion in Riyadh, Saudi Arabia: A Multicenter Retrospective Study.Journal of clinical medicine · 2026Article
153 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.